Literature DB >> 15301730

Pharmacokinetic difference between S-(+)- and R-(-)-etodolac in rats.

Jing-Min Shi1, Shun-Guo Lai, Chang-Jiang Xu, Geng-Li Duan, Duan Li.   

Abstract

AIM: To study whether etodolac enantiomers have pharmacokinetic difference after oral administration.
METHODS: Fourteen rats, divided into two groups randomly, were orally given S-(+)- or R-(-)-etodolac at a single dose of 20 mg/kg, respectively. Blood samples were collected before and at 5, 10, 20, 30 min and 1, 3, 6, 12, 24, 48, 72 h after treatment. The plasma samples were analyzed with a high-performance liquid chromatographic method.
RESULTS: The calibration curves were linear in the range of 0.5-50.0 mg/L (r=0.9999) to S-(+)-etodolac and 2.0-200.0 mg/L (r=0.9999) to R-(-)-etodolac, respectively. The main pharmacokinetic parameters of S-(+)- and R-(-)-etodolac were as follows: t1/2(lambdaz) 18+/-4 h vs 19.4+/-2.2 h, tmax 3.3+/-2.6 h vs 4+/-4 h; Cmax 29+/-6 mg/L vs 97+/-14 mg/L, AUC0-t 706+/-100 h.mg.L(-1) vs 2940+/-400 h mg.L(-1), CL(s) 0.030+/-0.006 L.kg(-1).h(-1) vs 0.0065+/-0.0010 L.kg(-1).h(-1) and V/F 0.25+/-0.22 L.kg(-1) vs 0.03+/-0.05 L.kg(-1). There was no significant difference in t1/2(lambdaz), and tmax between S-(+)- and R-(-)-etodolac (P>>0.05). The Cmax, and AUC0-t of R-(-)-etodolac were markedly higher (P<0.05), while the CL(s) and V/F were markedly lower than those of S-etolodac (P<0.05).
CONCLUSION: There is pharmacokinetic difference between S-(+)- and R-(-)- etodolac enantiomers in rats after oral administration.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15301730

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  5 in total

1.  Plasma IL-12 levels are suppressed in vivo by stress and surgery through endogenous release of glucocorticoids and prostaglandins but not catecholamines or opioids.

Authors:  Lee Shaashua; Ella Rosenne; Elad Neeman; Liat Sorski; Luba Sominsky; Pini Matzner; Gayle G Page; Shamgar Ben-Eliyahu
Journal:  Psychoneuroendocrinology       Date:  2014-01-07       Impact factor: 4.905

2.  Effect of beta blocker combined with COX-2 inhibitor on colonic anastomosis in rats.

Authors:  Barak Benjamin; Ofir Hazut; Lee Shaashua; Marganit Benish; Niv Zmora; Iris Barshack; Aviad Hoffman; Shamgar Ben-Eliyahu; Oded Zmora
Journal:  Int J Colorectal Dis       Date:  2010-06-16       Impact factor: 2.571

3.  Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis.

Authors:  Marganit Benish; Inbal Bartal; Yael Goldfarb; Ben Levi; Roi Avraham; Amiram Raz; Shamgar Ben-Eliyahu
Journal:  Ann Surg Oncol       Date:  2008-04-09       Impact factor: 5.344

4.  The effect of β-adrenergic blockade and COX-2 inhibition on healing of colon, muscle, and skin in rats undergoing colonic anastomosis.

Authors:  O Hazut; L Shaashua; M Benish; B Levi; L Sorski; B Benjamin; A Hoffman; O Zmora; S Ben-Eliyahu
Journal:  Int J Clin Pharmacol Ther       Date:  2011-09       Impact factor: 1.366

5.  Pharmacokinetic and pharmacodynamic studies of etodolac loaded vesicular gels on rats by transdermal delivery.

Authors:  Nimmathota Madhavi; Beeravelli Sudhakar; K V N Suresh Reddy; Jayanthi Vijaya Ratna
Journal:  Daru       Date:  2018-09-11       Impact factor: 3.117

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.